• H 89 2HCl for cAMP/PKA Signaling Assays

  2026-09-10

  H 89 2HCl enables practical interrogation of PKA-dependent phosphorylation, neurite remodeling, and cAMP-responsive signaling in biochemical and cell-based models. This guide combines concentration-aware workflow design with safeguards against vehicle effects and higher-dose inhibition of non-PKA kinases.

• OSMI-1: O-GlcNAc Transferase Inhibitor

  2026-09-10

  OSMI-1 is a cell-permeable O-GlcNAc transferase inhibitor that reduces protein O-GlcNAcylation and produces a reported IC50 of 2.7 μM. Its cellular and zebrafish benchmarks support controlled O-GlcNAcylation research while also requiring explicit cytotoxicity and acute-toxicity controls.

• Biotin-XX Tyramide Reagent for Surface Proteomics

  2026-09-09

  Biotin-XX Tyramide Reagent combines HRP-driven signal amplification with membrane-impermeant cell-surface labeling, making it useful for low-abundance targets in tissue imaging and proximity proteomics. Its long polar linker helps distinguish extracellular labeling from intracellular signal, supporting more selective astrocyte–neuron interface studies.

• JSH-23: Mapping NF-κB Control in Macrophages

  2026-09-09

  JSH-23 is an NF-κB inhibitor designed to separate p65-dependent transcription from upstream pathway activation. This article presents a practical, mechanistic framework for using it in macrophage assays, inflammasome studies, and the cisplatin-induced acute kidney injury model.

• Mc-Val-Cit-PABC-PNP ADC Linker Workflow

  2026-09-08

  Mc-Val-Cit-PABC-PNP is a cathepsin cleavable ADC peptide linker for research workflows involving lysosomal payload release during antibody-drug conjugate synthesis. It is highly soluble in DMSO but insoluble in water and ethanol, so it should be handled as a freshly prepared research reagent rather than an aqueous, diagnostic, or medical formulation.

• A-1210477 and the Logic of MCL-1 Dependence

  2026-09-07

  MCL-1 inhibition is most informative when treated as a functional test of apoptotic dependence rather than a simple expression-driven strategy. This thought-leadership guide connects the canonical MCL-1–BIM–BAX/BAK axis with experimental design, combination studies, competitive positioning, and the translational limits of A-1210477.

• Puromycin Aminonucleoside: Assay Design Logic

  2026-09-07

  Puromycin aminonucleoside is more than a nephrotoxic injury trigger: it is a tunable perturbation for linking transporter activity, podocyte morphology, proteinuria, and glomerular pathology. This guide adds a decision-centered framework and connects renal assay design with lessons from a mechanistic cancer study.

• Selonsertib: Reframing ASK1 in Metabolic Disease

  2026-09-05

  A translational perspective on how Selonsertib (GS-4997) can help dissect the intersection of ASK1 stress signaling, autophagy dysfunction, inflammation, and fibrosis in metabolic disease research.

• Anemoside B4, CD1d, and NLRP3 in Colitis

  2026-09-04

  This preprint identifies a macrophage-centered mechanism through which Anemoside B4 attenuates DSS-induced colitis, linking CD1d to the AKT-STAT1-PRDX1-NF-κB axis and NLRP3 inflammasome activation. Its combination of pharmacological treatment, cell-type analysis, and genetic depletion provides a useful framework for inflammation research, while the absence of peer review and direct target-binding evidence limits mechanistic certainty.

• Verapamil as a Causal Probe in Urothelial Hypoxia

  2026-09-04

  Verapamil ((±)-Verapamil) can do more than mark a treatment response: it can help separate calcium-linked, oxidative, and inflammasome-associated events in urothelial hypoxia assays. This evidence-led guide converts duration-resolved findings into a rigorous experimental interpretation framework.

• JSH-23 Workflows for NF-κB Inhibition

  2026-09-04

  JSH-23 is a pathway-positioning NF-κB inhibitor for separating p65 nuclear transcription from upstream IκB degradation. This guide shows how to use it in macrophage inflammation research, interpret cytokine results, and extend the workflow cautiously to viral inflammation and cisplatin-induced acute kidney injury models.

• BH3-Mimetics Target Apoptotic Dependence in Glioblastoma

  2026-09-03

  Koessinger et al. show that glioblastoma, including patient-derived stem-like cells, has increased dependence on the anti-apoptotic proteins BCL-xL and MCL-1. Their data support sequential BH3-mimetic inhibition as a strategy for apoptosis induction in BCL-XL-dependent cells and provide a mechanistic framework for targeting treatment-resistant disease.

• Dihydroartemisinin: From Chemistry to Assay Logic

  2026-09-02

  Dihydroartemisinin is more than an antimalarial research compound: it is a chemically defined probe for linking phenotype, pathway modulation, and assay quality. This guide uses evidence from a distinct antiplasmodial study to show how to design better cross-domain experiments without conflating mechanisms.

• BH3-Mimetics and Apoptotic Priming in Glioblastoma

  2026-09-02

  A 2022 Cell Death & Differentiation study shows that glioblastoma depends on elevated BCL-xL and MCL-1 activity, creating a therapeutically exploitable state of apoptotic priming. Its evidence supports sequential inhibition of these survival proteins as a strategy for targeting both bulk tumor cells and stem-like GBM populations.

• A-1210477 MCL-1 Inhibitor Apoptosis Workflows

  2026-09-01

  A-1210477 provides a selective in vitro strategy for testing whether cancer cells depend on MCL-1-mediated survival rather than simply responding to nonspecific toxicity. This workflow combines careful compound handling, dose-response profiling, mitochondrial apoptosis assays, and BAX/BAK-aware validation for more defensible cancer research results.

8114 records 1/541 page Next 12345 下5页 Last page